16-Epiestriol
16-Epiestriol (16-epi-Estriol; 16β,17β-Estriol) is a natural stereoisomer of estriol and an anti-inflammatory agent that targets UGT. The Ki values of 16-Epiestriol against human UGT1A10 and UGT2B7 are 98.1 μM and 162 μM, respectively. As a glucuronidation substrate, 16-Epiestriol can be modified at the 3-OH, 16-OH and 17-OH sites by various UGT enzymes; in liver microsomes, the modification mainly occurs at the 16-OH and 17-OH sites, while reactions take place at all three sites in intestinal microsomes. 16-Epiestriol acts on the phase II inflammatory process by blocking edema mediated by prostaglandins and leukocyte infiltration. It lacks glycogenic activity or any effect on blood glucose levels, and serves as an important candidate molecule in the research of inflammatory diseases.
For research use only. We do not sell to patients.
- CAS No.: 547-81-9
- Formula: C18H24O3
- Molecular Weight:288.38
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
|
Human Endogenous Metabolite |
In Vitro
16-Epiestriol (200 μM; 15-60 min) is targeted by recombinant human UGT1A1, UGT1A7, UGT1A8, UGT2B15, UGT1A3, UGT2A1, UGT2B4, and UGT2B17 which exhibit low-level glucuronidation activity towards it, with regioselectivity for the 3-OH or 16-OH[1].
16-Epiestriol (0.2-300 μM; 15-60 min) is targeted by pooled human intestine microsomes which preferentially catalyze its 3-OH glucuronidation with a Vmax of 4111 ± 94 pmol/min/mg and Km of 50 ± 3 μM, with secondary activity at the 16-OH and 17-OH[1].
16-Epiestriol (200 μM, 0.2-300 μM; 15-60 min) is targeted by recombinant human UGT2B7 which exhibits high activity towards it, catalyzing 16-OH glucuronidation with a Vmax of 3866 ± 788 pmol/min/mg, Km of 38.4 ± 11.4 μM, and substrate inhibition with a Ki of 162 ± 86.4 μM[1].
16-Epiestriol (0.2-300 μM; 15-60 min) is targeted by recombinant human UGT1A10-F93G which catalyzes its 3-OH glucuronidation with a Vmax of 2249 ± 201 pmol/min/mg and Km of 186 ± 28.0 μM, exhibiting lower turnover and higher Km than wild-type UGT1A10[1].
16-Epiestriol (0.2-300 μM; 15-60 min) is targeted by pooled human liver microsomes which preferentially catalyze its 16-OH glucuronidation with a Vmax of 8011 ± 106 pmol/min/mg and Km of 33 ± 1 μM, with far lower activity at the 3-OH and 17-OH[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
16-Epiestriol (60 μg/rat; s.c.; administered at 0, 2, 4, and 6 h) exhibits no significant glycogenic activity in adrenalectomized rats, as it does not alter plasma or hepatic glucose concentrations compared with untreated control groups[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, mean body weight ~200 g)[2]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced paw volume change to 0.22 mL (±0.05 SEM) at 1 h, 0.59 mL (±0.05 SEM) at 2 h, 0.71 mL (±0.05 SEM) at 3 h, and 0.50 mL (±0.06 SEM) at 5 h at 10 mg/kg.
Reduced paw volume change to 0.17 mL (±0.03 SEM) at 1 h, 0.44 mL (±0.05 SEM) at 2 h, 0.65 mL (±0.04 SEM) at 3 h, and 0.48 mL (±0.05 SEM) at 5 h at 20 mg/kg.
Reduced edema by 58% at 5 h compared to untreated controls at 20 mg/kg.
Reduced edema by 56% at 5 h on an equimolar basis, which is more than twice the efficacy of hydrocortisone.
Showed statistically significantly less edema at 5 h compared to untreated and hydrocortisone-treated groups (p < 0.001 by Student’s t-test) at 20 mg/kg.
-
Animal Model:Sprague-Dawley (adrenalectomized male, average body weight 185 g)[2]
-
Dosage:60 μg/rat per dose; total cumulative dose 240 μg/rat (0.832 μmol/rat)
-
Administration:s.c.; four doses at 0, 2, 4, and 6 h
-
Result:Resulted in median plasma glucose concentration of 79.0 mg/dL and median liver glucose concentration of 93.9 μg/g of liver.
Showed no statistically significant differences in median plasma or liver glucose concentrations relative to untreated control groups.
Chemical Information
-
CAS No. 547-81-9
-
Appearance Solid
-
Molecular Weight 288.38
-
Formula C18H24O3
-
Color White to off-white
-
SMILES
C[C@@]12[C@@H](O)[C@@H](O)C[C@@]1([H])[C@]3([H])CCC4=C(C=CC(O)=C4)[C@@]3([H])CC2
-
Synonyms
16-epi-Estriol; 16β,17β-Estriol
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (173.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sneitz N, et al. Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol. Drug Metab Dispos. 2013;41(3):582-591. [Content Brief]
[2]. Latman NS, et al. 16-epiestriol: an anti-inflammatory steroid without glycogenic activity. J Pharm Sci. 1994;83(6):874-877. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4676 mL | 17.3382 mL | 34.6765 mL | 86.6912 mL |
| 5 mM | 0.6935 mL | 3.4676 mL | 6.9353 mL | 17.3382 mL | |
| 10 mM | 0.3468 mL | 1.7338 mL | 3.4676 mL | 8.6691 mL | |
| 15 mM | 0.2312 mL | 1.1559 mL | 2.3118 mL | 5.7794 mL | |
| 20 mM | 0.1734 mL | 0.8669 mL | 1.7338 mL | 4.3346 mL | |
| 25 mM | 0.1387 mL | 0.6935 mL | 1.3871 mL | 3.4676 mL | |
| 30 mM | 0.1156 mL | 0.5779 mL | 1.1559 mL | 2.8897 mL | |
| 40 mM | 0.0867 mL | 0.4335 mL | 0.8669 mL | 2.1673 mL | |
| 50 mM | 0.0694 mL | 0.3468 mL | 0.6935 mL | 1.7338 mL | |
| 60 mM | 0.0578 mL | 0.2890 mL | 0.5779 mL | 1.4449 mL | |
| 80 mM | 0.0433 mL | 0.2167 mL | 0.4335 mL | 1.0836 mL | |
| 100 mM | 0.0347 mL | 0.1734 mL | 0.3468 mL | 0.8669 mL |